PolitiKit

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Provide input on a national strategy for drugs for rare diseases.

Provide input on pharmacare.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Support input into the consultation on draft guidance on decentralized clinical trials.

Recommend the creation of a Chief Patient Officer.

Support input regarding Canada’s pharmaceutical sovereignty.

Recommend the creation of a Patient Ombudsman.

Provide input on pharmacare.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Provide input on a national strategy for drugs for rare diseases.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Support input into the consultation on draft guidance on decentralized clinical trials.

Recommend the creation of a Patient Ombudsman.

Support input regarding Canada’s pharmaceutical sovereignty.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Provide input on a national strategy for drugs for rare diseases.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend the creation of a Patient Ombudsman.

Support input regarding Canada’s pharmaceutical sovereignty.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend the creation of a Chief Patient Officer.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Support input into the consultation on draft guidance on decentralized clinical trials.

Recommend the creation of a Chief Patient Officer.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Provide input on a national strategy for drugs for rare diseases.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input regarding Canada’s pharmaceutical sovereignty.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Recommend the creation of a Patient Ombudsman.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Support input into the consultation on draft guidance on decentralized clinical trials.

Provide input on a national strategy for drugs for rare diseases.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Recommend the creation of a Chief Patient Officer.

Provide input on pharmacare.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend the creation of a Patient Ombudsman.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input regarding Canada’s pharmaceutical sovereignty.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Support input into the consultation on draft guidance on decentralized clinical trials.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Provide input on a national strategy for drugs for rare diseases.

Provide input on pharmacare.

Recommend the creation of a Chief Patient Officer.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend the creation of a Patient Ombudsman.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Support input into the consultation on draft guidance on decentralized clinical trials.

Support input regarding Canada’s pharmaceutical sovereignty.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Recommend the creation of a Patient Ombudsman.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Provide input on pharmacare.

Provide input on a national strategy for drugs for rare diseases.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Recommend the creation of a Chief Patient Officer.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Support input into the consultation on draft guidance on decentralized clinical trials.

Support input regarding Canada’s pharmaceutical sovereignty.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Recommend the creation of a Patient Ombudsman.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Provide input on a national strategy for drugs for rare diseases.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Recommend the creation of a Chief Patient Officer.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Support input into the consultation on draft guidance on decentralized clinical trials.

Support input regarding Canada’s pharmaceutical sovereignty.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Provide input on pharmacare.

Support input regarding Canada’s pharmaceutical sovereignty.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend the creation of a Chief Patient Officer.

Provide input on a national strategy for drugs for rare diseases.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Recommend the creation of a Patient Ombudsman.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Support input into the consultation on draft guidance on decentralized clinical trials.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Provide input on a national strategy for drugs for rare diseases.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Recommend the creation of a Chief Patient Officer.

Support input regarding Canada’s pharmaceutical sovereignty.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Support input into the consultation on draft guidance on decentralized clinical trials.

Recommend the creation of a Patient Ombudsman.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input regarding Canada’s pharmaceutical sovereignty.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Provide input on a national strategy for drugs for rare diseases.

Recommend the creation of a Chief Patient Officer.

Provide input on pharmacare.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Recommend the creation of a Patient Ombudsman.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Support input into the consultation on draft guidance on decentralized clinical trials.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Provide input on pharmacare.

Support input regarding Canada’s pharmaceutical sovereignty.

Provide input on a national strategy for drugs for rare diseases.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input into the consultation on draft guidance on decentralized clinical trials.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Provide input on a national strategy for drugs for rare diseases.

Support input regarding Canada’s pharmaceutical sovereignty.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input into the consultation on draft guidance on decentralized clinical trials.